Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/IRCT20200305046700N1
IRCT20200305046700N1Not yet recruiting未知

The Efficacy of Bone Wax Application following Femoral Neck Osteotomy in Controlling Blood Loss in Total Hip Arthroplasty via Direct Anterior Approach

Tehran University of Medical Sciences0 sites100 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Not yet recruiting
Enrollment
100
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
no limit to no limit (—)
Sex
All

Inclusion Criteria

  • •Patients with hip degenerative joint disease (ICD-10-CM ; M16) with no age and sex limits, and not considering the severity of the disease, who are candidates for elective primary total hip arthroplasty based on the clinical and radiographic workup
  • •The patients should complete and sign the informed consent formula.
  • •The anesthesia method should be spinal anesthesia.

Exclusion Criteria

  • •Any bleeding disorder (ICD-10-CM; D65-D69) including platelet disorders like von Willebrand disease, and coagulation disorders like hemophilia
  • •History of venous thromboembolic accidents like deep vein thrombosis (DVT), pulmonary thromboembolism (PTE), cerebrovascular accidents (CVA), and myocardial infarction (MI)
  • •High-risk medical comorbidities like chronic kidney disease (GFR< 60 mL/min), liver, and heart failure (NYHA classes III , IV)
  • •Inflammatory arthritis of hip joint (ICD-10-CM; M05-M14) like rheumatoid arthritis
  • •Total hip arthroplasty due to acute proximal femoral fracture
  • •Total hip arthroplasty due to developmental dysplasia of hip (DDH) type II and more
  • •Revision total hip arthroplasty
  • •The use of antithrombotic drugs (ATC code; B01) including vitamin K antagonists (B01AA) like warfarin, platelet aggregation inhibitors (B01AA) like clopidogrel, heparin group (B01AB), Factor X inhibitors (B01AF) like rivaroxaban, direct thrombin inhibitors (B01AE) like dabigatran
  • •Impaired coagulation laboratory profile including INR>1.1, aPTT> 1.4, PT> 13.5, or thrombocytopenia < 150,000 per microliter
  • •Any anesthesia method other than spinal anesthesia
  • •Patient cannot or do not want to continue participating in the study or follow-up for any reason

Investigators

Similar Trials

Terminated
Not Applicable
Bone Wax Use for Hemostasis During Primary Unilateral Total Knee ArthroplastyTotal Knee Replacement
NCT04992052Northwell Health52
Completed
Phase 1
Clinical study of Absorbable Bone Wax in Neurological SurgeryThe ability of new absorbable bone wax in stopping bone bleeding during craniotomy or craniectomy will be evaluated together with the handling properties.
TCTR20151116003ational Science and Technology Development Agency20
Not yet recruiting
Phase 4
Efficacy of bone graft,growth factor (CGF) membrabne and coronally advanced flap (CAF) in treatment of gingival recession.
CTRI/2019/03/018247Terna Dental College
Recruiting
Not Applicable
to study the effect of preservative free drug- eye drop to reduce pain in patients undergoing laser eye surgery to correct refractive errors
CTRI/2016/01/006536ethradhama super speciality eye hospital50
Active, not recruiting
Phase 1
Investigation to assess the efficacy of benzyl benzoate emulsion versus permethrin creme for scabies treatmentScabies
EUCTR2022-000660-22-ATandeskrankenhaus Salzburg100